134 reports of this reaction
4.5% of all BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE reports
#1 most reported adverse reaction
DRUG INEFFECTIVE is the #1 most commonly reported adverse reaction for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, manufactured by Topco Associates LLC. There are 134 FDA adverse event reports linking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE to DRUG INEFFECTIVE. This represents approximately 4.5% of all 2,981 adverse event reports for this drug.
Patients taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE who experience drug ineffective should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DRUG INEFFECTIVE is moderately reported among BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE users, representing a notable but not dominant share of adverse events.
In addition to drug ineffective, the following adverse reactions have been reported for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE:
The following drugs have also been linked to drug ineffective in FDA adverse event reports:
DRUG INEFFECTIVE has been reported as an adverse event in 134 FDA reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DRUG INEFFECTIVE accounts for approximately 4.5% of all adverse event reports for BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, making it one of the most commonly reported side effect.
If you experience drug ineffective while taking BACITRACIN ZINC, NEOMYCIN SULFATE, POLYMYXIN B SULFATE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.